The addition of ViaCell’s product ViaCord and its highly qualified sales and marketing organization provides PerkinElmer with a leading offering in the rapidly growing cord blood banking business, as well as an enhanced ability to reach obstetric professionals and prospective parents, the company said.
ViaCell’s ViaCord product offering allows expectant families to preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders.
PerkinElmer added that ViaCell customers will continue to benefit from ViaCord’s high-quality cord blood banking offering and expertise, and now will have access to a wider range of neonatal, prenatal and maternal health solutions from PerkinElmer.